Allarity Therapeutics (ALLR) News
NASDAQ: ALLRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ALLR news summary
We found 4 recent headlines mentioning Allarity Therapeutics (ALLR): 2 in the past week and 4 in the past 30 days, most often from GlobeNewswire. ALLR is making an outsized move today, down 9.25% at $0.785, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Allarity Therapeutics Granted U.S. Patent for Stenoparib’s Clinical Dosing Regimen, with Protection Into 2045", was published by GlobeNewswire on Nov 18, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Allarity Therapeutics headlines
- Allarity Therapeutics Granted U.S. Patent for Stenoparib’s Clinical Dosing Regimen, with Protection Into 2045Patent with 36 allowed claims covering twice-daily treatment in ovarian cancer and other solid tumorsGlobeNewswire
- Allarity Therapeutics Expands Phase 2 Stenoparib Trial to Three Ovarian Cancer Patient CohortsInvestigator-supported move capitalizes on strong enrollment momentum and encouraging early clinical observationsGlobeNewswire
- Allarity Therapeutics Reports Third Quarter 2026 Results and Provides Full Year 2026 Financial Guidance- Ended third quarter with $24.1 million in cash and restricted cash - Expects positive fourth quarter earnings between $0.01 and $0.04 per shareGlobeNewswire
- Allarity Therapeutics Secures First Commercial Agreement Under New CLIA Laboratory Services Strategy, Establishing Potential Path to Additional Recurring Revenue- Agreement complements revenue from standard gene expression and DRP® servicesGlobeNewswire